We engineer
and manufacture
platelets.
Inspired by platelet biology to save lives
Thrombocytopenia
(lead program 1)
Developing universal* platelets for treatment in patients with, or at risk of, HLA immune-refractoriness.
Tissue-targeted cargo delivery
(lead program 2)
Using our unique CAR-PLT® technology for shielded delivery of miRNA/siRNA or proteins to specific target tissues.
Regenerative medicine
Using engineered platelets in wound healing, anti-inflammatory and immunomodulating applications.
Culture of therapeutic stem cells
Using platelet lysate produced from our universal platelets to boost cell proliferation.
* engineered to be HLA-null
HemostOD: a swiss-based preclinical company
Founded in 2020, HemostOD is a biotech company based at the EPFL Innovation Park in Lausanne, Switzerland.
We are a preclinical stage company developing applications based on our proprietary platform to engineer and manufacture universal platelets.
A unique & scalable
platelet manufacturing
platform
Immortalization of hematopoietic progenitors (stem) cells from a single donor.
Engineering of cells to introduce custom features, modifying the platelet surface and/or content for controlled release.
Differentiation into a practically unlimited source of megakaryocytes, the platelet progenitor cells.
Ex-vivo generation of platelets in a robust, fast and scalable manufacturing process.
HemostOD cell line
Engineered
HemostOD cell line
Megakaryocytes
Platelets
Partnering opportunities
- Thrombocytopenia,
- Tissue-targeted cargo delivery technology (CAR-PLT®),
- Regenerative medicine,
- Culture of therapeutic stem cells (platelet lysate),
and beyond.
HemostOD enters EIT Health’s Gold Track Programme
HemostOD has been recognized as a promising healthcare company by a jury of experts. The team will now receive tailored support to grow the company.
Partnering with the Swiss Biotech Center
HemostOD partners with the Swiss Biotech Center to pre-industrialize its technology. Thanks to this new partnership HemostOD will benefit from solid expertise and state-of-the-art infrastructure
Tech Seed loan
HemostOD receives CHF 100’000 from the Foundation for Technological Innovation (FIT).